{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:58:44Z","timestamp":1773280724365,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.nano.2011.10.015","type":"journal-article","created":{"date-parts":[[2011,11,23]],"date-time":"2011-11-23T14:35:03Z","timestamp":1322058903000},"page":"1034-1041","source":"Crossref","is-referenced-by-count":80,"title":["Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies"],"prefix":"10.1016","volume":"8","author":[{"given":"Joana","family":"Ara\u00fajo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria L.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Mallandrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliana B.","family":"Souto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana C.","family":"Calpena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2011.10.015_bb0005","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.survophthal.2007.06.004","article-title":"Triamcinolone acetonide in ocular therapeutics","volume":"52","author":"Jermak","year":"2007","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.nano.2011.10.015_bb0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2010.08.028","article-title":"Barrier analysis of periocular drug delivery to the posterior segment","volume":"148","author":"Ranta","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2011.10.015_bb0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijpharm.2006.05.053","article-title":"Biodegradable scleral implants as new triamcinolone acetonide delivery systems","volume":"322","author":"Felt-Baeyens","year":"2006","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2011.10.015_bb0020","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s11095-009-0042-9","article-title":"New techniques for drug delivery to the posterior eye segment","volume":"27","author":"Eljarrat-Binstock","year":"2010","journal-title":"Pharm Res"},{"key":"10.1016\/j.nano.2011.10.015_bb0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0169-409X(01)00193-4","article-title":"Transscleral drug delivery for posterior segment disease","volume":"52","author":"Geroski","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2011.10.015_bb0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jconrel.2003.11.002","article-title":"Comparative study of morphine diffusion from sustained release polymeric suspensions","volume":"95","author":"Morales","year":"2004","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2011.10.015_bb0035","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.nano.2009.02.003","article-title":"Nanomedicines for ocular NSAIDs: safety on drug delivery","volume":"5","author":"Ara\u00fajo","year":"2009","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2011.10.015_bb0040","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/02713681003760168","article-title":"Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs","volume":"35","author":"Souto","year":"2010","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.nano.2011.10.015_bb0045","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s11095-008-9812-z","article-title":"Intraocular sustained-release delivery systems for triamcinolone acetonide","volume":"26","author":"Mansoor","year":"2009","journal-title":"Pharm Res"},{"key":"10.1016\/j.nano.2011.10.015_bb0050","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.addr.2007.04.012","article-title":"Nanostructured lipid carriers (NLC) in cosmetic dermal products","volume":"59","author":"M\u00fcller","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2011.10.015_bb0055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-5173(02)00180-1","article-title":"Nanostructured lipid matrices for improved microencapsulation of drugs","volume":"242","author":"M\u00fcller","year":"2002","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2011.10.015_bb0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"Solid lipid nanoparticles: production, characterization and applications","volume":"47","author":"Mehnert","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2011.10.015_bb0065","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijpharm.2006.01.040","article-title":"Preparation and characteristics of monostearin nanostructured lipid carriers","volume":"314","author":"Hu","year":"2006","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2011.10.015_bb0070","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijpharm.2008.01.045","article-title":"Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation","volume":"357","author":"Puglia","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2011.10.015_bb0075","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/02652040500435295","article-title":"Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization","volume":"23","author":"Souto","year":"2006","journal-title":"J Microencapsul"},{"key":"10.1016\/j.nano.2011.10.015_bb0080","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijpharm.2007.05.060","article-title":"Nanostructured lipid carrier (NLC) based gel of celecoxib","volume":"346","author":"Joshi","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2011.10.015_bb0085","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijpharm.2010.03.034","article-title":"Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications","volume":"393","author":"Ara\u00fajo","year":"2010","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2011.10.015_bb0090","series-title":"LJS, inventor. Arzneistofftr\u00e4ger aus festen Lipidteilchen, Feste Lipidnanosph\u00e4ren (SLN)","author":"M\u00fcller","year":"1996"},{"key":"10.1016\/j.nano.2011.10.015_bb0095","first-page":"221","article-title":"Nanoparticle characterization: a comprehensive physicochemical approach","volume":"1","author":"Magenheim","year":"1991","journal-title":"STP Pharma Sci"},{"key":"10.1016\/j.nano.2011.10.015_bb0100","series-title":"Doc. Ref: EMEA7CHMP\/EWP\/192217\/2009. Guideline on validation of bioanalytical methods. London","author":"European Medicines Agency","year":"2009"},{"key":"10.1016\/j.nano.2011.10.015_bb0105","first-page":"1893","article-title":"Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning","volume":"36","author":"Olsen","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.nano.2011.10.015_bb0110","series-title":"Current Step 4 version Parent Guideline dated 27 October 1994 [complementary Guideline on Methodology dated 6 November 1996 incorporated in November","article-title":"Validation of analytical procedures: text and methodology Q2(R1)","author":"ICH","year":"2005"},{"key":"10.1016\/j.nano.2011.10.015_bb0115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jconrel.2010.11.009","article-title":"Ophthalmic delivery of cyclosporine a by punctal plugs","volume":"150","author":"Gupta","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2011.10.015_bb0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0378-5173(92)90032-W","article-title":"On the non-Gaussian distribution of human skin permeabilities","volume":"86","author":"Williams","year":"1992","journal-title":"Intl J Pharm"},{"key":"10.1016\/j.nano.2011.10.015_bb0125","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/10826079608005534","article-title":"Chromatographic method validation: a review of current practices and procedures. II. Guidelines for primary validation parameters","volume":"19","author":"Jenke","year":"1996","journal-title":"J Liq Chrom Relat Tech"},{"key":"10.1016\/j.nano.2011.10.015_bb0130","series-title":"Design of controlled release drug delivery systems","first-page":"1","article-title":"Application of pharmacokinetics and pharmacodynamics in the design of controlled delivery systems","author":"Uchizono","year":"2006"},{"key":"10.1016\/j.nano.2011.10.015_bb0135","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.exer.2005.08.007","article-title":"A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide","volume":"82","author":"Robinson","year":"2006","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.nano.2011.10.015_bb0140","first-page":"1181","article-title":"Diffusion of high molecular weight compounds through sclera","volume":"41","author":"Ambati","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.nano.2011.10.015_bb0145","series-title":"Transdermal and topical drug delivery","first-page":"27","author":"Williams","year":"2003"},{"key":"10.1016\/j.nano.2011.10.015_bb0150","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1208\/pt070364","article-title":"Evaluation of alternative strategies to optimize ketorolac transdermal delivery","volume":"7","author":"Puglia","year":"2006","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.nano.2011.10.015_bb0155","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10717540590952591","article-title":"Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery","volume":"12","author":"Jain","year":"2005","journal-title":"Drug Deliv"},{"key":"10.1016\/j.nano.2011.10.015_bb0160","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0939-6411(03)00067-5","article-title":"Solid lipid nanoparticle and microemulsion for topical delivery of triptolide","volume":"56","author":"Mei","year":"2003","journal-title":"Eur J Pharm Biopharm"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963411005272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963411005272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T08:52:10Z","timestamp":1543395130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963411005272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S1549963411005272"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2011.10.015","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}